Peiyan Kong

Dr. Peiyan Kong


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
LZLidan Zhu
Lidan Zhu
QLQiong Li
Qiong Li
XWXiaoguo Wang
Xiaoguo Wang
JLJun Liao
Jun Liao
WZWei Zhang
Wei Zhang
PKPeiyan Kong
Peiyan Kong
Dysregulation of cytokines and growth factors is a general feature of tumor microenvironment, and unraveling the expression spectrum of cytokine and growth factor in niche is of utmost importance. Here, we evaluated cytokine profiling of bone marrow serum samples in AML patients and healthy controls. Protein expression profiling of serum from nine AML patients and five healthy controls was obtained using a biotinylated antibody chip. A total of 507 cytokines and growth factors were analyzed. Compared with healthy people, AML patients expressed 31 signature proteins, among which, 27 were significantly higher expressed and 4 proteins were lower. When patients were divided into favorable and poor prognosis, 12 signature proteins were significantly differentially expressed between these two groups. Furthermore, in order to identify the accuracy of cytokine expression profiles, we verified and analyzed the expression of THBS1 (Thrombospondin 1) in 116 patients and 9 healthy people. We found that THBS1 was lowly expressed in AML patients, which might be induced by promoter methylation, and patients with low THBS1 possessed shorter survivor time. Our data indicated that we successfully unveil differentially expressed proteins in AML patients using a biotinylated antibody chip; among them, THBS1 may be a potential therapeutic target for AML patients' treatment.

15 April 2014
Verified
Journal Article
Closed access
DZDongfeng Zeng
Dongfeng Zeng
JWJinliang Wang
Jinliang Wang
PKPeiyan Kong
Peiyan Kong
CCCheng Chang
Cheng Chang
JLJieping Li
Jieping Li
JLJiali Li
Jiali Li

10 May 2023 in Cancer Medicine
Verified
Journal Article
Open access
HYHan Yao
Han Yao
CZCheng Zhang
Cheng Zhang
XTXu Tan
Xu Tan
JLJieping Li
Jieping Li
XYXiaolin Yin
Xiaolin Yin
XZXi Zhang
Xi Zhang
Background: Refractory and relapsed acute myeloid leukemia (r/rAML) is associated with a difficult prognosis; clinical trials are typically suggested despite lack of a recognized standard of care. Combinatorial chemotherapy regimens utilized for r/rAML salvage play a crucial role in battling this invasive phase. Although it is characterized by a low response rate, CLAG is a traditional regimen used in r/rAML. We aimed to compare the efficacy and toxicity of CLAG+PLD to explore whether there was any improvement with the addition of pegylated liposomal doxorubicin (PLD) to CLAGMethods: A total of 110 r/rAML patients were retrospectively analyzed from February 2017 to June 2020 at the Medical Center of Hematology, XinQiao Hospital, the 303rd Hospital of the Chinese People's Liberation Army, and Central Hospital of Chang Sha, Hunan Province. The response, overall survival (OS), disease‐free survival (DFS), and side effects in 110 r/rAML patients were evaluated retrospectively. Of these, 55 patients were administered CLAG+PLD, while 55 patients received CLAG alone as salvage therapy.Results: In the CLAG+PLD group, there were 27 (49.1%) cases of complete response (CR) with no measurable residual disease (MRD−), 12 (21.8%) cases of CR with positive MRD (MRD+), 5 (9.1%) cases of partial response (PR), 11 (20%) cases of no response (NR), and no cases of death during the cycles. The response rates in the CLAG group were lower: CR was reached in 24 (46.6%) patients with MRD−, 6 (10.9%) patients with MRD+, 10 (18.2%) patients with PR, 13 (23.6%) patients with NR, and 2 (3.6%) patients who passed away, one from infection and the other from cerebral hemorrhage. The median OS and DFS were not attained in the CLAG+PLD group during the 2‐year OS and DFS follow‐up, while both values were 10 months in the CLAG group (p = 0.023 and p = 0.045, respectively). The results of the Cox regression analysis for the CLAG+PLD group were strongly illustrative of the importance of hematopoietic stem cell transplantation (HSCT) following salvage therapy. No increased toxicity was observed in the CLAG+PLD group.Conclusion: CLAG+PLD is a potential salvage regimen for r/r AML that has a similar toxicity profile to CLAG and that improves response rates, 2‐year OS, and DFS relative to CLAG.

22 June 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
YFYimei Feng
Yimei Feng
TCTing Chen
Ting Chen
YZYun Zhang
Yun Zhang
HYHan Yao
Han Yao
PWPing Wang
Ping Wang
PKPeiyan Kong
Peiyan Kong
Introduction: While allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be a curative regimen for acute myeloid leukemia (AML), relapse of AML remains a serious risk post-transplantation. Once relapsed, salvage options are limited and management of AML is difficult. Here we designed a prospective study to examine the efficacy and tolerability of maintenance therapy with azacytidine (AZA) plus low-dose lenalidomide (LEN) to prevent relapse after allo-HSCT for AML patients (ChiCTR2200061803).Methods: AML patients post-allo-HSCT were treated with AZA (75 mg/m2 for 7 days), followed by LEN (5 mg/m2, day 10-28), and a 4-week resting interval, which was defined as one treatment cycle. A total of 8 cycles was recommended. Results: 37 patients were enrolled, 25 patients received at least 5 cycles, and 16 patients finished all 8 cycles. With a median follow-up time of 608 (43-1440) days, the estimated 1-year disease free survival (DFS) was 82%, cumulative incidence of relapse (CIR) was 18%, and overall survival (OS) was 100%. Three patients (8%) had grade 1-2 neutropenia without fever; one patient developed grade 3-4 thrombocytopenia and minor subdural hematoma; 4/37 patients (11%) developed chronic GVHD with a score of 1-2, without requiring systemic treatment; No patient developed acute GVHD. After AZA/LEN prophylaxis, increasing numbers of CD56+NK and CD8+ T, and decreasing of CD19+ B cells were observed. Discussion: Azacitidine combined with low-dose lenalidomide was observed to be an effective relapse prophylaxis option after allo-HSCT in AML patients, and can be administered safely without significantly increasing the risk of GVHD, infection and other AEs.Clinical Trial Registration: www.chictr.org, identifier ChiCTR2200061803.

16 February 2024 in Acta Haematologica
Verified
Journal Article
Closed access
PDF file
TCTing Chen
Ting Chen
JLJiaLi Li
JiaLi Li
XWXiao Wei
Xiao Wei
HYHan Yao
Han Yao
LZLiDan Zhu
LiDan Zhu
PKPeiyan Kong
Peiyan Kong
Introduction: Steroid-refractory cGVHD (SR-cGVHD) presents new great challenges for treatment. We have reported that imatinib monotherapy was effective to SR-cGVHD, but the CR rate was not satisfactory and the benefit was not showed specific to some target organs, previously. Imatinib and statin drugs have been recognized to regulate T-cell function, statins also have been demonstrated endothelia protection, but whether this combination therapy was able to improve the efficacy remains unknown. Therefore, we designed this prospective, single-arm, open-label trial to investigate the efficacy of imatinib-based combination therapy in the treatment of SR-cGVHD for the first time. Methods: Sixty SR-cGVHD patients were entered into this trial to investigate the combination of imatinib mesylate and atorvastatin calcium for the treatment of SR-cGVHD. The primary endpoint included the overall response rate (ORR) after 6 months of combined treatment. The secondary endpoints included an evaluation of survival, changes in T-cell subsets, and adverse events. Results: At baseline, 45% (27/60) of patients had moderate cGVHD, and 55.0% (33/60) of patients had severe cGVHD. At the 6-month follow-up, a clinical response was achieved in 70.0% of patients, and a complete response (CR) was achieved in 26.7%. A total of 11.7% (7/60) of patients stopped immunosuppressive therapy at this point. After 6 months of treatment, the ORR rates of the liver, skin, eyes, and oral cavity were 80.6%, 78.1%, 61.5%, and 60.9%, respectively, with the liver also having the highest CR of 58.1%. The patients with moderate cGVHD had a better CR rate than those with severe cGVHD (55.6% vs. 3.0%, p < 0.0001). The overall survival in patients with ORR was improved (p = 0.0106). Lung involvement is an independent risk factor to affected ORR achievement (p = 0.021, HR = 0.335, 95% CI: 0.133–0.847), and the dosage of steroids was reduced in ORR patients. In clinical response patients, the ratio of CD8+ T cells (p = 0.0117) and Th17 cells (p = 0.0171) decreased, while the number of Treg cells (p = 0.0147) increased after 3 months. The most common adverse events were edema, nausea, and neutropenia, which were 13.3%, 11.7%, and 11.7%, respectively. Conclusion: Combination treatment with imatinib mesylate and atorvastatin calcium was effective in treating SR-cGVHD and significantly decreased target organ injury, especially liver damage, indicating that T-cell regulatory function may play an important role in this process.

1 January 2024 in Blood and Genomics Discovery
Verified
Journal Article
Open access
PDF file
GCGuo Chen
Guo Chen
YMYingying Ma
Yingying Ma
TXTAN XU
TAN XU
MWMaihong Wang
Maihong Wang
QWQin Wen
Qin Wen
XZXi Zhang
Xi Zhang
Acute promyelocytic leukemia (APL) with CPSF6-RARG fusion gene is a rare leukemia. Patients with this fusion are resistant to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), as well as conventional chemotherapy with anthracycline plus cytosine arabinoside. Therefore, it is necessary to explore new protocols for these patients to improve remission and survival. In this case, a 21-year-old female with APL of CPSF6-RARG fusion gene was resistant to daunorubicin combined with cytarabine, ATRA, and ATO. Then the patient underwent a combination of homoharringtonine and pegylated liposomal doxorubicin chemotherapy (homoharringtonine 2 mg/day from day 1-7, Ara-C 15 mg/m 2 every 12 hours from day 1-7, Peg-Dox 40 mg/m 2 divided over 3 days from day 1-3 and rhG-CSF 300 μg/day from day 0-8). Following one month of treatment, the patient reached CR. And after another two cycles of the HADG protocol with medium-dose Ara-C treatment, the CPSF6-RARG turned negative. Then the patient successfully received stem cell transplantation. Currently, the patient has survived disease-free for more than 2 years. This study indicates that a combination of homoharringtonine and pegylated liposomal doxorubicin chemotherapy is a successful treatment plan for AML resembling APL with the CPSF6-RARG fusion gene. However, further validation in larger sample sizes is required.